Skip to main content

Table 3 Intervals between carboplatin infusion and HD and AUCs of free carboplatin in previous studies of carboplatin-based chemotherapy in HD patients

From: Cancer screening and treatment in patients with end-stage renal disease: remaining issues in the field of onco-nephrology

  Number of patients Disease Carboplatin dose Interval between carboplatin infusion and hemodialysis (h) AUC (mg × min/ml) of free carboplatin
(A) Hemodialysis was initiated soon after carboplatin infusion (1~2 h after infusion).
Kurata et al. (1994) [77] 1 Ovarian carcinoma 240 mg/m2 (cycle 1) 1 3.14
240 mg/m2 (cycle 2) 2 5.09
Suzuki et al. (1997) [78] 1 Merkel cell carcinoma 150 mg (cycle 1) 1 4.6
150 mg (cycle 2) 2 4.8
Watanabe et al. (2002) [52] 1 Ovarian carcinoma 125 mg (cycle 1) 1.5 2.21
Furuya et al. (2003) [79] 1 Urothelial carcinoma 125 mg 1 2.44
Takezawa et al. (2008) [80] 1 SCLC 250 mg/m2 (cycle 1) 1 4.10
275 mg/m2 (cycle 2) 1 4.16
Kamata et al. (2009) [81] 1 NSCLC 150 mg/m2 1 4.9
Yoshida et al. (2009) [82] 1 Ovarian carcinoma 125 mg 1 0.98
Kondo et al. (2012) [83] 1 Cancer of unknown primary 125 mg (cycle 1) 1 3.03
125 mg (cycle 2) 1 3.44
125 mg (cycle 3) 1 3.5
Hiraike et al. (2012) [54] 1 SCLC 480 mg (cycle 1) 1 13.45
170 mg (cycle 2) 1 5.74
(B) Hemodialysis was initiated long after carboplatin infusion (16~24 h after infusion).
Motzer et al. (1990) [84] 2 Germ cell tumor 100 mg/m2 24 6.7
Germ cell tumor 100 mg/m2 24 6.9
Chatelut et al. (1994) [48] 1 Ovarian carcinoma 100 mg (cycle 1) 24 3.5
150 mg (cycle 2) 24 6.7
150 mg (cycle 3) 24 6.06
Watanabe et al. (2002) [52] 1 Ovarian carcinoma 125 mg (cycle 2) 16 4.43
125 mg (cycle 3) 16 4.75
125 mg (cycle 4) 16 4.13
Yokoyama et al. (2006) [85] 1 Ovarian carcinoma 200 mg (cycle 1) 24 8.03
200 mg (cycle 2) 16 5.69
Oguri et al. (2010) [51] 2 NSCLC 100 mg 24 4.7
Ovarian cancer 125 mg 24 6.1
Kodama et al. (2010) [86] 1 Ovarian carcinoma 100 mg (cycle 1) 24 3.48
150 mg (cycle 2) 24 4.23
175 mg (cycle 3) 24 5.55
150 mg (cycle 4) 24 4.59
  1. SCLC small cell lung cancer, NSCLC non-small cell lung cancer